Phase I Clinical Trial of TO-203 - Safety Trial in Patients with HDM (House Dust Mite)-induced Asthma
Phase 1
- Conditions
- HDM-induced asthma
- Registration Number
- JPRN-jRCT2080221584
- Lead Sponsor
- TORII PHARMACEUTICAL CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 48
Inclusion Criteria
1) Positive specific IgE against HDM (>=IgE Class 3)
2) Positive HDM-allergen scratch test
Exclusion Criteria
1) A clinical history of perennial allergic asthma and/or rhinitis caused by an allergen to which the patient is regularly exposed, and sensitised (except HDM)
2) Previous treatment by immunotherapy with HDM
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does TO-203 target in HDM-induced asthma?
How does TO-203 compare to standard-of-care treatments for allergic asthma?
Are there specific biomarkers associated with TO-203's efficacy in HDM-induced asthma?
What adverse events are reported in phase I trials of TO-203 for respiratory conditions?
What are the potential combination therapies involving TO-203 and other anti-asthma agents?